Evidence map›Paper›PMID 36592186›Full record

SynthesisClinical research in cardiology : official journal of the German Cardiac Society2023

Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.

Pedro E P Carvalho, Thiago M A Veiga, Ana C Simões E Silva, Douglas M Gewehr, Caroline S Dagostin, Amanda Fernandes, Guilherme Nasi, Rhanderson Cardoso

Open access · bronzeAbstract readComparative StudyMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical research in cardiology : official journal of the German Cardiac Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. SGLT2-is in Acute Heart Failure.Journal of clinical medicine · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Pedro E P CarvalhoDepartment of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.ORCID http://orcid.org/0000-0002-0918-6759
Thiago M A VeigaDepartment of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
Ana C Simões E SilvaUnit of Pediatric Nephrology, Department of Pediatrics, Interdisciplinary Laboratory of Medical Investigation, UFMG, Belo Horizonte, Brazil.
Douglas M GewehrCuritiba Heart Institute (INCOR Curitiba), Curitiba, Paraná, Brazil.
Caroline S DagostinScience and Technology, Denton Cooley Institute of Research, Curitiba, Paraná, Brazil.
Amanda FernandesDivision of Cardiology, Boston University, Boston, MA, USA.
Guilherme NasiDivision of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Rhanderson CardosoHeart and Vascular Center, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. rcardoso2@bwh.harvard.edu.
Universidade Federal de Minas Gerais · BRBoston University · USBrigham and Women's Hospital · USInstituto de Neurologia de Curitiba · BRInstituto de Tecnologia do Paraná · BRMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe sought to compare cardiovascular outcomes, renal function, and diuresis in patients receiving standard diuretic therapy for acute heart failure (AHF) with or without the addition of SGLT2i. METHODS AND

resultsSystematic search of three electronic databases identified nine eligible randomized controlled trials involving 2,824 patients. The addition of SGLT2i to conventional therapy for AHF reduced all-cause death (odds ratio [OR] 0.75; 95% CI 0.56-0.99; p = 0.049), readmissions for heart failure (HF) (OR 0.54; 95% CI 0.44-0.66; p < 0.001), and the composite of cardiovascular death and readmissions for HF (hazard ratio 0.71; 95% CI 0.60-0.84; p < 0.001). Furthermore, SGLT2i increased mean daily urinary output in liters (mean difference [MD] 0.45; 95% CI 0.03-0.87; p = 0.035) and decreased mean daily doses of loop diuretics in mg of furosemide equivalent (MD -34.90; 95% CI [- 52.58, - 17.21]; p < 0.001) without increasing the incidence worsening renal function (OR 0.75; 95% CI 0.43-1.29; p = 0.290).

conclusionSGLT2i addition to conventional diuretic therapy reduced all-cause death, readmissions for HF, and the composite of cardiovascular death or readmissions for HF. Moreover, SGLT2i was associated with a higher volume of diuresis with a lower dose of loop diuretics.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsDiureticsHumansKidneyRandomized Controlled Trials as TopicSodium Potassium Chloride Symporter InhibitorsDiureticsSodium-Glucose Transporter 2 InhibitorsSodium Potassium Chloride Symporter InhibitorsAcute heart failureDiuresisRenal functionSodium-glucose cotransporter-2 (SGLT2) inhibitors

Identifiers

PMID36592186
PMCPMC9807098
OpenAlexW4313424030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.